| |
Spot 1 (day 1 post examination)
|
Spot 2 (day 3–5 post examination)
|
|---|
|
U-Na (mmol/L)
|
|
Placebo
|
79 (41;105)
|
50 (31;135)
|
|
Furosemide
|
57 (27;98)†
|
62 (32;151)*
|
|
U-K (mmol/L)
|
|
Placebo
|
26 (15;37)
|
27 (14;44)
|
|
Furosemide
|
34 (19;52)†
|
30 (17;58)*
|
|
U-Cl (mmol/L)
|
|
Placebo
|
78 (53;126)
|
63 (40;129)
|
|
Furosemide
|
67 (38;116)
|
70 (45;186)
|
|
U-Creatinine (mmol/L)
|
|
Placebo
|
4 (3;6)
|
5 (4;16)
|
|
Furosemide
|
8 (4;13)†
|
5 (3;13)*
|
|
U-Osmolality (mmol/L)
|
|
Placebo
|
392 (200;467)
|
269 (195;710)*
|
|
Furosemide
|
430 (236;663)†
|
358 (214;740)*
|
|
U-Albumin (mg/L)
|
|
Placebo
|
2 (1;5)
|
4 (2;7)
|
|
Furosemide
|
5 (3;6)†
|
4 (2;4)
|
|
U-ENaCγ (ng/ml)
|
|
Placebo
|
0.29 (0.18;0.44)
|
0.35 (0.19;0.85)
|
|
Furosemide
|
0.57 (0.27;0.92)
|
0.37 (0.21;0.92)
|
|
U-AQP2 (ng/ml)
|
|
Placebo
|
0.40 (0.19;0.49)
|
0.37 (0.26;0.81)*
|
|
Furosemide
|
0.68 (0.27;0.95)
|
0.36 (0.29;1.08)*
|
|
U-NGAL (ng/ml)
|
|
Placebo
|
8.5 (3.8;23.8)
|
9.5 (2.8;22.3)*
|
|
Furosemide
|
19.5 (4.0;40.5)
|
14.0 (3.0;25.5)*
|
|
U-KIM (ng/ml)
|
|
Placebo
|
0.13 (0.08;0.17)
|
0.22 (0.09;0.35)*
|
|
Furosemide
|
0.40 (0.09;0.57)
|
0.20 (0.08;0.49)*
|
- u-Na Urinary concentrations of sodium, u-K potassium, u-Cl chloride, creatinine, albumin, u-ENaCγ γ-fraction of the epithelial sodium channel, u-AQP2 aquaporin 2, u-NGAL neutrophil gelatinase-associated lipocalin and u-KIM-1 kidney injury, molecule-1. Data are shown as medians with 25 and 75 percentiles in brackets. Wilcoxon signed rank test was used to test statistically significant difference from spot 1, * = p < 0.05, and from Placebo, † = p < 0.05
